{"page":{"totalFilteredElements":78},"studies":[{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11855,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-10T08:43:49+01:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11945,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-01T09:33:13+02:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen und verwandter Erkrankungen in Verbindung mit einer prospektiven Biomaterialsammlung","eudractNumber":null,"id":1513,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[],"nctNumber":"NCT02872987","phase":null,"recruitmentStart":"2009-09-15T12:21:43+02:00","shortTitle":"GMALL Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)","eudractNumber":"2022-000760-21","id":7902,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-07-13T08:50:01+02:00","shortTitle":"GMALL-EVOLVE","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label<br /><div><br /></div><div>DRKS00033264</div>","eudractNumber":null,"id":10626,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-01T14:53:16+01:00","shortTitle":"Harbour","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)</div>","eudractNumber":"2021-000330-33","id":6920,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym2","name":"Morbus Hodgkin"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04837859","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-06T08:39:04+01:00","shortTitle":"INDIE","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"The Registry of the European Mantle Cell Lymphoma Network (EMCL-R)","eudractNumber":null,"id":8672,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-01-24T09:08:41+01:00","shortTitle":"International MCL Registry (EMCL-R)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma</div>","eudractNumber":"2020-000562-41","id":7242,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04989803","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-01-01T09:01:37+01:00","shortTitle":"KT-US-499-0150","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","eudractNumber":"2025-524403-80-00","id":11989,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07479797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-09-29T08:37:13+02:00","shortTitle":"KT-US-740-0603 PALISADES-2","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</div>","eudractNumber":"2020-005843-21","id":7303,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05041309","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-02-16T09:01:53+01:00","shortTitle":"KT-US-982-5968","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]}]}